Vancomycin-resistant enterococci

Critical Care Clinics

Volumn 29, Issue 4, 2013, Pages 841-852

  Rubinstein, Ethan ^a   Keynan, Yoav ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Critical care; Enterococcus; Gram positive cocci; Infection; Resistant pathogen; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; RIFAMPICIN; SULBACTAM; TEDIZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; ENTEROCOCCAL INFECTION; HOSPITAL INFECTION; HUMAN; HYPERBILIRUBINEMIA; IMMUNOCOMPROMISED PATIENT; LEUKOPENIA; LIVER FUNCTION; LOADING DRUG DOSE; LOEFFLER PNEUMONIA; MITOCHONDRIAL TOXICITY; MYALGIA; NAUSEA; NEPHROTOXICITY; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOPHLEBITIS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING; WOUND INFECTION;

CRITICAL CARE; ENTEROCOCCUS; GRAM-POSITIVE COCCI; INFECTION; RESISTANT PATHOGEN; VANCOMYCIN;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS INFECTION; DRUG THERAPY, COMBINATION; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84884920134     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.06.006     Document Type: Review

References (53)

1. Graninger W., Ragette R. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992, 15:49.
2. Gullberg R.M., Homann S.R., Phair J.P. Enterococcal bacteremia: analysis of 75 episodes. Rev Infect Dis 1989, 11:74.
3. Stevenson K.B., Murray E.W., Sarubbi F.A. Enterococcal meningitis: report of four cases and review. Clin Infect Dis 1994, 18:233.
4. Buchino J.J., Ciambarella E., Light I. Systemic group D streptococcal infection in newborn infants. Am J Dis Child 1979, 133:270.
5. Elvy J., Porter D., Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. JAntimicrob Chemother 2008, 61:461.
6. Zeana C., Kubin C.J., Della-Latta P., et al. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001, 33:477.
7. Tush G.M., Huneycutt S., Phillips A., et al. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998, 26:1460.
8. Birmingham M.C., Rayner C.R., Meagher A.K., et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003, 36:159.
9. El-Khoury J., Fishman J.A. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003, 5:121.
10. Meka V.G., Gold H.S. Antimicrobial resistance to linezolid. Clin Infect Dis 2004, 39:1010.
11. Vinh D.C., Rubinstein E. Linezolid: a review of safety and tolerability. JInfect 2009, 59(Suppl 1):S59-S74.
12. Benvenuto M., Benziger D.P., Yankelev S., et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006, 50:3245.
13. Waites K.B., Duffy L.B., Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and invitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006, 50:3479.
14. Schutt A.C., Bohm N.M. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009, 43:2108.
15. Grayson M.L., Eliopoulos G.M., Wennersten C.B., et al. Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991, 35:2180.
16. Rice L.B., Bellais S., Carias L.L., et al. Impact of specific pbp5 mutations on expression of beta-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother 2004, 48:3028.
17. Mainardi J.L., Legrand R., Arthur M., et al. Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. JBiol Chem 2000, 275:16490.
18. Gavalda J., Len O., Miro J.M., et al. Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007, 146:574.
19. Reynolds P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989, 8:943.
20. Arthur M., Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993, 37:1563.
21. Reynolds P.E., Depardieu F., Dutka-Malen S., et al. Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol Microbiol 1994, 13(6):1065.
22. Van Bambeke F., Chauvel M., Reynolds P.E., et al. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants. Antimicrob Agents Chemother 1999, 43:41.
23. Bourgeois-Nicolaos N., Massias L., Couson B., et al. Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis invivo. JInfect Dis 2007, 195:1480.
24. Pogue J.M., Paterson D.L., Pasculle A.W., et al. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007, 28:1382.
25. Gonzales R.D., Schreckenberger P.C., Graham M.B., et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357:1179.
26. Rahim S., Pillai S.K., Gold H.S., et al. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003, 36:E146.
27. Munoz-Price L.S., Lolans K., Quinn J.P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005, 41:565.
28. Arias C.A., Panesso D., McGrath D.M., et al. Genetic basis for invivo daptomycin resistance in enterococci. NEngl J Med 2011, 365:892.
29. Hershberger E., Donabedian S., Konstantinou K., et al. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004, 38:92.
30. Kehoe L.E., Snidwongse J., Courvalin P., et al. Structural basis of Synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. JBiol Chem 2003, 278:29963.
31. Moellering R.C., Linden P.K., Reinhardt J., et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. JAntimicrob Chemother 1999, 44:251.
32. Werner G., Gfrörer S., Fleige C., et al. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. JAntimicrob Chemother 2008, 61:1182.
33. Karanfil L.V., Murphy M., Josephson A., et al. Acluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992, 13:195.
34. Handwerger S., Raucher B., Altarac D., et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993, 16:750.
35. Ramsey A.M., Zilberberg M.D. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009, 30:184.
36. Uttley A.H., George R.C., Naidoo J., et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989, 103:173.
37. Livornese L.L., Dias S., Samel C., et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992, 117:112.
38. DiazGranados C.A., Zimmer S.M., Klein M., et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005, 41:327.
39. Bonten M.J., Slaughter S., Ambergen A.W., et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998, 158:1127.
40. Duckro A.N., Blom D.W., Lyle E.A., et al. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch Intern Med 2005, 165:302.
41. Fridkin S.K., Edwards J.R., Courval J.M., et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001, 135:175.
42. Weinstein J.W., Roe M., Towns M., et al. Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996, 17:36.
43. Donskey C.J., Chowdhry T.K., Hecker M.T., et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. NEngl J Med 2000, 343:1925.
44. Ostrowsky B.E., Trick W.E., Sohn A.H., et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. NEngl J Med 2001, 344:1427.
45. Elizaga M.L., Weinstein R.A., Hayden M.K. Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci. Clin Infect Dis 2002, 34:441.
46. D'Agata E.M., Gautam S., Green W.K., et al. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002, 34:167.
47. Perencevich E.N., Fisman D.N., Lipsitch M., et al. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004, 38:1108.
48. Climo M.W., Sepkowitz K.A., Zuccotti G., et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009, 37:1858.
49. Matsumura S., Simor A.E. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998, 27:1554.
50. Raad I., Hachem R., Hanna H., et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001, 45:3202.
51. Stevens M.P., Edmond M.B. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005, 41:1134.
52. Arias C.A., Torres H.A., Singh K.V., et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of invivo loss of the vanA gene cluster. Clin Infect Dis 2007, 45:1343.
53. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. JHosp Med 2007, 2:343.